Join
Live feed
·
PRReleasevia Quantisnow
Pliant Therapeutics Inc. logo

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
PLRX· Pliant Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PLRX (Pliant Therapeutics Inc.) and more on Quantisnow.